This is a working overview of copper(II) complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-02. Anything still debated is marked as such rather than presented as settled.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
=== Pharmacokinetics === Metabolism of myristicin yields 3-methoxycatechol and enzymatically forms 5-allyl-1-methoxy-2,3-dihydroxybenzene (oxidation of the methylenedioxy group). Myristicin is also transformed into demethylenylmyristicin, dihydroxymyristicin, and elemicin is transformed into O-demethylelemicin, O-demethyldihydroxyelemicin, and safrole. There has been speculation that myristicin might be converted into the psychedelic MMDA, but this has not been demonstrated in humans. However, two nitrogen-containing metabolites of myristicin have been identified in the urine of rats and guinea pigs following oral or intraperitoneal administration. The major basic ninhydrin-positive urinary metabolite of myristicin in the rat is 3-piperidyl-1-(3′methoxy-4′,5′-methylenedioxyphenyl)-1-propanone, while the major basic ninhydrin-positive urinary metabolite of the guinea pig is 3-pyrrolidinyl-1-(3′methoxy-4′,5′-methylenedioxyphenyl)-1-propanone. Equivalent nitrogen-containing metabolites have also been identified for safrole and elemicin, including the dimethylamine, piperidine and pyrrolidine forms. Whether these aminated metabolites are involved in the reported psychoactive and hallucinogenic effects of botanical sources of these allylbenzenes like nutmeg is not known.
== Technology == Vaxess's business plan is based around a technology developed by Tufts University Professors Fiorenzo Omenetto and David Kaplan. The technology uses a silk-derived protein called fibroin to stabilize vaccines so that they can be shipped and stored without refrigeration, eliminating the need for the cold chain. Vaxess is working with vaccine manufacturers to develop heat-stable vaccines and targeting a product launch by 2019.
== Applications == Countercurrent chromatography and related liquid-liquid separation techniques have been used on both industrial and laboratory scale to purify a wide variety of chemical substances. Separation realizations include proteins, DNA, Cannabidiol (CBD) from Cannabis Sativa antibiotics, vitamins, natural products, pharmaceuticals, metal ions, pesticides, enantiomers, polyaromatic hydrocarbons from environmental samples, active enzymes, and carbon nanotubes. Countercurrent chromatography is known for its high dynamic range of scalability: milligram to kilogram quantities purified chemical components may be obtained with this technique. It also has the advantage of accommodating chemically complex samples with undissolved particulates.
Sources: en.wikipedia.org
In 2013, Michael Klare compared in RealClearPolitics tensions between Russia and the West to the ongoing proxy conflict between Saudi Arabia and Iran. Oxford Professor Philip N. Howard argued that a new cold war was being fought via the media, information warfare, and cyberwar. Some observers, including Syrian president Bashar al-Assad, judged the Syrian civil war to be a proxy war between Russia and the United States, and even a "proto-world war". In January 2016, senior UK government officials were reported to have registered their growing fears that "a new cold war" was now unfolding in Europe: "It really is a new Cold War out there. Right across the EU we are seeing alarming evidence of Russian efforts to unpick the fabric of European unity on a whole range of vital strategic issues". In April 2018, relations deteriorated over a potential US-led military strike in Middle East after the Douma chemical attack in Syria, which was attributed to the Syrian Army by rebel forces in Douma, and poisoning of the Skripals in the UK. The secretary-general of the United Nations, António Guterres, told a meeting of the UN Security Council that "the Cold War was back with a vengeance". He suggested the dangers were even greater, as the safeguards that existed to manage such a crisis "no longer seem to be present". Dmitri Trenin supported Guterres' statement, but added that it began in 2014 and had been intensifying since, resulting in US-led strikes on the Syrian government on 13 April 2018.
=== Characterization === Cox described Logan Roy as a "mysterious character in many ways. I have a lot of empathy for him. I think he's very misunderstood. I think he's a tragic figure", and compared him to Shakespeare's tragic kings, such as Henry IV. "Obviously there's Lear connotations, but it's also the father dealing with a child in his son Hal and not understanding him." David Rasche, who plays Karl Muller, suggested to Jesse Armstrong that his character became a confessor to Logan, "But I don't think Jesse wanted that. Jesse wanted Logan Roy, a man alone." Cox thinks of Logan as "quite Puritan [...] Logan's a bastard, but he's not an indecent bastard." On Logan's romantic relationships he has said "He clearly loves Marcia. There's this idea that he had this affair with Rhea, but I'm not sure that happened. Both Holly [Hunter] and I felt that hadn't actually happened, [...] The kids thinking they were having an affair was more them projecting", but also added that "he's not good at relationships at all. The female relationships in his life have been pretty disastrous". By the final season Cox noted that, Colin and Kerry, Logan's bodyguard and assistant respectively, were "the two people who matter to him most." Cox has expressed that he believes that Logan's greatest weakness was that "he loves his children desperately." In interviews with The New Yorker, Armstrong agreed with Cox that Logan loves his children, even if he had done "things which are antithetical to what most people would consider to be love."
Reticulocytosis is a laboratory finding in which the number of reticulocytes (immature red blood cells) in the bloodstream is elevated. Reticulocytes account for approximately 0.5% to 2.5% of the total red blood cells in healthy adults and 2% to 6% in infants, but in reticulocytosis, this percentage rises. Reticulocytes are produced in the bone marrow and then released into the bloodstream, where they mature into fully developed red blood cells between 1–2 days. Reticulocytosis often reflects the body's response to conditions rather than an independent disease process and can arise from a variety of causes such as blood loss or anemia.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.